radoncreview_org (@radoncreview) 's Twitter Profile
radoncreview_org

@radoncreview

Our mission is to create the most comprehensively updated Rad Onc reference and to make it available for free, forever, for all.

ID: 1174388354995146755

linkhttps://www.RadOnc.org calendar_today18-09-2019 18:23:10

892 Tweet

3,3K Takipçi

623 Takip Edilen

radoncreview_org (@radoncreview) 's Twitter Profile Photo
radoncreview_org
@radoncreview

4 months ago

Here is a provocative paper for stage III. This data is suggestive of Rituximab + RT being curative treatment, with none of the 11 patients who received peri-radiation Rituximab experiencing relapse. DLBCL-free survival is a patient-centric endpoint! ncbi.nlm.nih.gov/pubmed/32316464

Here is a provocative paper for stage III. This data is suggestive of Rituximab + RT being curative treatment, with none of the 11 patients who received peri-radiation Rituximab experiencing relapse. DLBCL-free survival is a patient-centric endpoint! ncbi.nlm.nih.gov/pubmed/32316464